Enfortumab/Pembrolizumab Dosing Schedule ‘Groundbreaking’ in Urothelial Cancer


Nazy Zomorodian, NP, spoke with CancerNetwork® about the unique dosing schedule of enfortumab vedotin plus pembrolizumab following its accelerated approval by the FDA in advanced/metastatic urothelial cancer.

Using both enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) in the clinical trial setting for patients with advanced or metastatic urothelial cancer who could receive cisplatin-based chemotherapy could be considered groundbreaking, according to Nazy Zomorodian, NP.1,2

In a conversation with CancerNetwork® prior to the regimen’s accelerated FDA approval, Zomorodian, director of the Genitourinary Clinical Trials Unit and assistant professor and Nurse Practitioner for the Department of Urology at UCLA Health, discussed the combination’s survival benefit in addition to its “groundbreaking” dosing schedule.

The regulatory decision was based on results from cohorts A and K of the phase 1b/2 EV-103 or KEYNOTE-869 trial (NCT03288545). Data from the study included an objective response rate of 68% (95% CI, 59%-76%) in patients who received the combination (n = 121), as well as a 12% complete response rate. For patients in cohort A—single arm cohorts treating patients with enfortumab vedotin and pembrolizumab —the median duration of response was 22 months (range, 1+ to 46+), however, it was not reached in cohort K—wherein patients received enfortumab vedotin alone or in combination with pembrolizumab.


We had enfortumab [monotherapy] for urothelial cancer, metastatic and nonmetastatic for awhile. Then we also had pembrolizumab by itself for the treatment of urothelial cancer. Both of these drugs, indeed, showed that it improved progression-free survival and overall survival in this population of patients.

It was groundbreaking to use both drugs in the clinical trial setting because of the way that these they are scheduled. The way that the administration is done for enfortumab is [that it’s given on] day 1, day 8, and day 15, then the patient gets a week off. The cycles are 28 days. Pembrolizumab, a form of immunotherapy, is [given] every 3 weeks.


  1. FDA grants accelerated approval to enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial carcinoma. News release. FDA. April 3, 2023. Accessed April 3, 2023. http://bit.ly/3nGtsjh
  2. Rosenberg JE, Milowsky M, Ramaurthy C, et al. Study EV-103 cohort K: antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC). Ann Oncol. 2022;33(suppl 7):S808-S869. doi:10.1016/annonc/annonc1089
Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
Sean Dineen, MD, highlights the removal of abdominal wall lesions and other surgical strategies that may help manage symptoms in patients with cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content